Abilita Bio is an innovation-driven biotechnology company focused on enabling the discovery of transformative therapeutics targeting the most challenging membrane proteins, such as GPCRs, Ion Channels and Transporters. Our key advantage is the unparalleled capability to generate high-quality antigens for even the toughest membrane proteins. Using our Enabled Membrane Protein (EMP™) directed evolution platform, we can rapidly generate enhanced target variants with transformative improvements in properties, which remove the roadblocks to antibody discovery. Our patented EMP™ technology has been validated through multiple research collaborations with top-tier pharma and biotech partners. In 2019, we in began building internal antibody discovery capabilities and expertise to pair with the EMP™ platform, which has positioned us to establish research partnerships that span from target evolution to lead identification.
Abilita Bio, Inc. is presenting as part of the NIH Innovation Zone.